QQQ   423.11 (-0.64%)
AAPL   166.76 (-0.74%)
MSFT   405.10 (-1.64%)
META   502.30 (+1.65%)
GOOGL   155.96 (+0.32%)
AMZN   178.91 (-1.31%)
TSLA   150.16 (-3.40%)
NVDA   844.72 (+0.52%)
AMD   154.32 (+0.19%)
NIO   4.01 (+2.56%)
BABA   68.90 (+0.12%)
T   16.23 (+0.68%)
F   12.00 (-0.33%)
MU   112.58 (-3.22%)
GE   153.59 (-1.34%)
CGC   8.15 (+25.58%)
DIS   112.80 (-0.12%)
AMC   2.91 (-2.35%)
PFE   25.31 (-0.43%)
PYPL   62.09 (-1.85%)
XOM   118.17 (-0.39%)
QQQ   423.11 (-0.64%)
AAPL   166.76 (-0.74%)
MSFT   405.10 (-1.64%)
META   502.30 (+1.65%)
GOOGL   155.96 (+0.32%)
AMZN   178.91 (-1.31%)
TSLA   150.16 (-3.40%)
NVDA   844.72 (+0.52%)
AMD   154.32 (+0.19%)
NIO   4.01 (+2.56%)
BABA   68.90 (+0.12%)
T   16.23 (+0.68%)
F   12.00 (-0.33%)
MU   112.58 (-3.22%)
GE   153.59 (-1.34%)
CGC   8.15 (+25.58%)
DIS   112.80 (-0.12%)
AMC   2.91 (-2.35%)
PFE   25.31 (-0.43%)
PYPL   62.09 (-1.85%)
XOM   118.17 (-0.39%)
QQQ   423.11 (-0.64%)
AAPL   166.76 (-0.74%)
MSFT   405.10 (-1.64%)
META   502.30 (+1.65%)
GOOGL   155.96 (+0.32%)
AMZN   178.91 (-1.31%)
TSLA   150.16 (-3.40%)
NVDA   844.72 (+0.52%)
AMD   154.32 (+0.19%)
NIO   4.01 (+2.56%)
BABA   68.90 (+0.12%)
T   16.23 (+0.68%)
F   12.00 (-0.33%)
MU   112.58 (-3.22%)
GE   153.59 (-1.34%)
CGC   8.15 (+25.58%)
DIS   112.80 (-0.12%)
AMC   2.91 (-2.35%)
PFE   25.31 (-0.43%)
PYPL   62.09 (-1.85%)
XOM   118.17 (-0.39%)
QQQ   423.11 (-0.64%)
AAPL   166.76 (-0.74%)
MSFT   405.10 (-1.64%)
META   502.30 (+1.65%)
GOOGL   155.96 (+0.32%)
AMZN   178.91 (-1.31%)
TSLA   150.16 (-3.40%)
NVDA   844.72 (+0.52%)
AMD   154.32 (+0.19%)
NIO   4.01 (+2.56%)
BABA   68.90 (+0.12%)
T   16.23 (+0.68%)
F   12.00 (-0.33%)
MU   112.58 (-3.22%)
GE   153.59 (-1.34%)
CGC   8.15 (+25.58%)
DIS   112.80 (-0.12%)
AMC   2.91 (-2.35%)
PFE   25.31 (-0.43%)
PYPL   62.09 (-1.85%)
XOM   118.17 (-0.39%)
Free Trial
NASDAQ:ZIOP

ZIOPHARM Oncology (ZIOP) Stock Price, News & Analysis

→ Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad)
Free ZIOP Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.82
▼
$1.39
52-Week Range
N/A
Volume
2.13 million shs
Average Volume
2.01 million shs
Market Capitalization
$187.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
ZIOP stock logo

About ZIOPHARM Oncology Stock (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

ZIOP Stock News Headlines

February 10, 2024 | investing.com
Alx Oncology Holdings (ALXO)
January 31, 2024 | reuters.com
CG Oncology Inc
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
December 18, 2023 | markets.businessinsider.com
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
September 15, 2023 | newsweek.com
WBSPH 2024 - Oncology
August 29, 2023 | thestreet.com
Gauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results
June 21, 2023 | investing.com
Ziopharm’s palifosfamide fails in first-line STS…
June 15, 2023 | morningstar.com
ALX Oncology Holdings Inc Ordinary Shares
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
June 9, 2023 | finance.yahoo.com
Intratumoral Cancer Therapies Global Market Report 2023
May 11, 2023 | marketwatch.com
Natural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.co
March 27, 2023 | marketwatch.com
Global Drugs for Non-small Cell Lung Cancer Market Size 2023 to 2026 Size and Share Survey Report
March 27, 2023 | marketwatch.com
Chronic Lymphocytic Leukemia Market 2023 Size and Forecast to 2030
February 23, 2023 | finance.yahoo.com
USA Community Oncology Services Market Competitor Scenario - Market Positioning And Player-Based Strategies, By The Business Research Company
February 18, 2023 | finance.yahoo.com
Verdi Oncology's Horizon Oncology Announces Agreement with Integra Connect to Bring Value-Based Care to Central Indiana
February 18, 2023 | marketwatch.com
Global Gene Therapy in Oncology Market Size is Booming Across the Globe and Witness Huge Growth by Key Players to 2030 By VMReports
February 18, 2023 | seekingalpha.com
iBio shares more than double in value after hours on new immuno-oncology target program
January 24, 2023 | marketwatch.com
Cancer Care Market is booming in near Future 2023-2028
January 13, 2023 | finanznachrichten.de
Nerviano Medical Sciences S.r.l.: Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor Asset
January 12, 2023 | yahoo.com
Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor Asset
January 5, 2023 | thestreet.com
Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation
November 26, 2022 | marketwatch.com
Cancer Care Market : Share, Industry Size, Opportunities, Analysis and Forecast to 2028 with Top Countries Data
November 12, 2022 | finance.yahoo.com
Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor
October 20, 2022 | finance.yahoo.com
Gadeta Appoints Scientific Advisory Board and Provides Business Update
September 27, 2022 | marketwatch.com
Global Cancer Care Market Size and Scope 2022 Research Report by Consumption, Revenue, Regions, Gross Margin and Forecast to 2026
September 24, 2022 | finanznachrichten.de
Celyad Oncology SA: Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction
September 7, 2022 | finance.yahoo.com
Candel Therapeutics Announces Two Executive Leadership Appointments
See More Headlines
Receive ZIOP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
4/18/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ZIOP
CUSIP
98973P10
CIK
1107421
Web
www.ziopharm.com
Phone
(617) 259-1970
Fax
617-241-2855
Employees
105
Year Founded
2005

Profitability

EPS (Most Recent Fiscal Year)
($0.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-79,980,000.00
Net Margins
N/A
Pretax Margin
-22,544.97%
Return on Equity
-92.84%
Return on Assets
-72.46%

Debt

Debt-to-Equity Ratio
0.18
Current Ratio
3.43
Quick Ratio
3.43

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.58 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
216,146,000
Free Float
204,906,000
Market Cap
$187.12 million
Optionable
Optionable
Beta
1.71

Social Links

7 Stocks to Own Before the 2024 Election Cover
7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Kevin S. BoyleKevin S. Boyle
    Chief Executive Officer & Director
  • Timothy M. Cunningham
    Chief Financial Officer
  • Lynn M. Ferrucci
    EVP-Human Resources, Administration & IT
  • Raffaele Baffa
    Chief Medical Officer & Head-Research
  • Eleanor M. de Groot
    General Manager-Cell Therapy & Executive VP

Key Competitors

View All Competitors

ZIOP Stock Analysis - Frequently Asked Questions

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) issued its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04. The biotechnology company had revenue of $0.40 million for the quarter. During the same period in the previous year, the business posted ($0.10) EPS.

What other stocks do shareholders of ZIOPHARM Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN), Gilead Sciences (gild), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Inovio Pharmaceuticals (INO), Arena Pharmaceuticals (ARNA) and Immunomedics (IMMU).

This page (NASDAQ:ZIOP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Emergency: Biden's $20 Trillion Mistake Could Cost YOU!
GoldenCrest Metals
Next President (Not Trump. Not Biden.)
The Freeport Society
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
The only accurate crypto trading system I know …
Weiss Ratings